For your convenience, we have created interactive editions of several investor documents and packed them into this eKit. These interactive documents are designed for comfortable reading and easy navigation.

Click here to access the investor kit.

Amgen - Recent Press Releases
06/19/15Amgen Presents Open-Label Extension Data From Ongoing Phase 2 Study Of AMG 334 In The Prevention Of Episodic MigrainePrinter Friendly Version
06/18/15Results From Phase 3 Trial Show Vectibix® (Panitumumab) Improves Overall Survival In Chemorefractory Wild-Type KRAS Metastatic Colorectal Cancer Versus Best Supportive CarePrinter Friendly Version
06/10/15Amgen To Discuss Details Of Repatha™ (Evolocumab) Biologics License Application For The Treatment Of High CholesterolPrinter Friendly Version
06/08/15Amgen To Present At The Goldman Sachs Global Healthcare ConferencePrinter Friendly Version
06/05/15Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular DiseasePrinter Friendly Version
06/01/15Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And AtezolizumabPrinter Friendly Version
06/01/15Amgen Presents Phase 3 Data At ASCO Showing Prolia® (Denosumab) Significantly Reduced Bone Fractures In Breast Cancer Patients Receiving Aromatase InhibitorsPrinter Friendly Version
05/31/15Amgen Initiates Phase 3 Study Evaluating Once-Weekly Kyprolis® (carfilzomib) in Patients With Relapsed And Refractory Multiple MyelomaPrinter Friendly Version
05/29/15Amgen And Merck Announce Expansion Of Collaboration To Support Studies Of Talimogene Laherparepvec In Combination With KEYTRUDA® (Pembrolizumab) In Patients With Head And Neck CancerPrinter Friendly Version
05/29/15Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney DiseasePrinter Friendly Version